Tina Papagiannopoulos counsels clients on a range of regulatory, policy and compliance matters involving the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC), in addition to assisting with various litigation and transactional matters involving life sciences companies. With a focus on therapeutics, she advises on product development and regulatory approval, marketing exclusivities, advertising and promotion, post-approval obligations, and responses to investigation and enforcement actions. Tina also offers guidance to FDA-regulated clients to help them navigate issues that have the potential to materially impact their businesses, including formal agency meetings and processes involving public comment and petitioning.